Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumabFRONTIERS IN IMMUNOLOGYIF5.92024-12-100OAAI
Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular CarcinomaLIVER CANCERIF9.12024-09-021OAAI
Expansion of effector regulatory T cells in steroid responders of severe alcohol-associated hepatitisLIVER TRANSPLANTATIONIF3.92024-04-171PRE
Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative studyFRONTIERS IN ONCOLOGYIF3.32024-02-280OAAI
Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinomaHEPATOLOGYIF15.82024-02-153PRE